Absorbed dose distributions in patients with bone metastases from hormone refractory prostate cancer treated with Re-186 HEDP

被引：0
|
作者：
Bacelar, A. M. Denis [1 ]
Divoli, A. [2 ]
Chittenden, S. [2 ]
Du, Y. [2 ]
Dearnaley, D. P. [1 ]
O'Sullivan, J. M. [3 ]
Flux, G. D. [2 ]
机构：
[1] Inst Canc Res, Sutton, Surrey, England
[2] Royal Marsden Hosp, Sutton, Surrey, England
[3] Queens Univ Belfast, Belfast City Hosp, Belfast, Antrim, North Ireland
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2013年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S188 / S188
页数：1
相关论文
共 50 条
  • [31] Dose escalation study with Re-188HEDP in prostate cancer patients with osseous metastases.
    Palmedo, H
    Guhlke, S
    Bender, H
    Sartor, J
    Schoeneich, G
    Risse, J
    Gruenwald, F
    Knapp, FF
    Biersack, HJ
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 218P - 218P
  • [32] Prediction of response of skeletal metastases from cancer of the prostate to high activity 186Re HEDP therapy.
    McCready, VR
    O'Sullivan, J
    Dearnaley, D
    Cook, G
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 316P - 316P
  • [33] Clinical implications of bone formation and resorption markers after palliative therapies for painful osseous metastases with 186Re-HEDP in prostate cancer patients
    Zafeirakis, A.
    Papatheodorou, G.
    Limouris, G. S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S289 - S289
  • [34] Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis REPLY
    Biersack, Hans J.
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (08) : 1332 - 1332
  • [35] Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases
    Marnix G. E. H. Lam
    Bernard A. Zonnenberg
    European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35 : 1394 - 1395
  • [36] Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases
    Lam, Marnix G. E. H.
    Zonnenberg, Bernard A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (07) : 1394 - 1395
  • [37] Effect of high dose Rhenium 186 HEDP with stem cell support on skeletal metastases in prostate cancer
    Al-Deen, A
    McCready, VR
    Dearnaley, DP
    Treleaven, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S344 - S344
  • [38] The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid
    Oh, William K.
    Proctor, Kevin
    Nakabayashi, Mari
    Evan, Carolyn
    Tormey, Lauren K.
    Daskivich, Timothy
    Antras, Lucia
    Smith, Michael
    Neary, Maureen P.
    Duh, Mei Sheng
    CANCER, 2007, 109 (06) : 1090 - 1096
  • [39] Phase I study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer
    deKlerk, JMH
    vanhetSchip, AD
    Zonnenberg, BA
    vanDijk, A
    Quirijnen, JMSP
    Blijham, GH
    vanRijk, PP
    JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (02) : 244 - 249
  • [40] Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases
    Palmedo, H
    Bender, H
    Dierke-Dzierzon, C
    Carl, UM
    Risse, J
    Krebs, D
    Biersack, HJ
    CLINICAL NUCLEAR MEDICINE, 1999, 24 (09) : 643 - 648
12345